Literature DB >> 12606559

Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices.

Zhenglin Gu1, Ping Zhong, Zhen Yan.   

Abstract

Deposition of fibrillar aggregates of the beta-amyloid peptide (Abeta) is a key pathologic feature during the early stage of Alzheimer's disease. The initial neuronal responses to Abeta in cortical circuits and the regulation of Abeta-induced signaling remain unclear. In this study, we found that exposure of cortical slices to Abeta(1-42) or Abeta(25-35) induced a marked increase in the activation of protein kinase C (PKC) and Ca(2+)/calmodulin-dependent kinase II (CaMKII), two enzymes critically involved in a variety of cellular functions. Activation of M1 muscarinic receptors, but not nicotinic receptors, significantly inhibited the Abeta activation of PKC and CaMKII. Increasing inhibitory transmission mimicked the M1 effect on Abeta, whereas blocking GABA(A) receptors eliminated the M1 action. Moreover, electrophysiological evidence shows that application of Abeta to cortical slices induced action potential firing and enhanced excitatory postsynaptic currents, whereas muscarinic agonists potently increased inhibitory postsynaptic currents. These results suggest that Abeta activates PKC and CaMKII through enhancing excitatory activity in glutamatergic synaptic networks. Activation of M1 receptors inhibits Abeta signaling by enhancing the counteracting GABA(ergic) inhibitory transmission. Thus the muscarinic reversal of the Abeta-induced biochemical and physiological changes provides a potential mechanism for the treatment of Alzheimer's disease with cholinergic enhancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606559     DOI: 10.1074/jbc.M209892200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex.

Authors:  Joanna P Tyszkiewicz; Zhenglin Gu; Xun Wang; Xiang Cai; Zhen Yan
Journal:  J Physiol       Date:  2003-11-28       Impact factor: 5.182

Review 2.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 3.  Aβ Influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer's Disease.

Authors:  Ana Gabriela Henriques; Joana Machado Oliveira; Liliana Patrícia Carvalho; Odete A B da Cruz E Silva
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 4.  Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease.

Authors:  Robert A Rissman; William C Mobley
Journal:  J Neurochem       Date:  2011-03-28       Impact factor: 5.372

5.  2-(4-methyl-thiazol-5-yl) ethyl nitrate maleate-potentiated GABAA receptor response in hippocampal neurons.

Authors:  Xiao-Mei Jiang; Wei-Ping Wang; Zhi-Hui Liu; Hua-Jing Yin; Hao Ma; Nan Feng; Ling Wang; Hai-Hong Huang; Xiao-Liang Wang
Journal:  CNS Neurosci Ther       Date:  2018-07-24       Impact factor: 5.243

6.  Modulation of neuronal excitability by serotonin-NMDA interactions in prefrontal cortex.

Authors:  Ping Zhong; Eunice Y Yuen; Zhen Yan
Journal:  Mol Cell Neurosci       Date:  2008-03-25       Impact factor: 4.314

7.  A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.

Authors:  Jana K Shirey; Ashley E Brady; Paulianda J Jones; Albert A Davis; Thomas M Bridges; J Phillip Kennedy; Satyawan B Jadhav; Usha N Menon; Zixiu Xiang; Mona L Watson; Edward P Christian; James J Doherty; Michael C Quirk; Dean H Snyder; James J Lah; Allan I Levey; Michelle M Nicolle; Craig W Lindsley; P Jeffrey Conn
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

Review 8.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

9.  Serotonin facilitates long-term depression induction in prefrontal cortex via p38 MAPK/Rab5-mediated enhancement of AMPA receptor internalization.

Authors:  Ping Zhong; Wenhua Liu; Zhenglin Gu; Zhen Yan
Journal:  J Physiol       Date:  2008-07-24       Impact factor: 5.182

10.  Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex.

Authors:  Xun Wang; Ping Zhong; Zhenglin Gu; Zhen Yan
Journal:  J Neurosci       Date:  2003-10-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.